Komori
Other Disclosures4883Modalis Therapeutics CorporationPharmaceuticals

Notice Regarding the Decision to Grant a Japanese Patent for Technology Related to CRISPR-GNDM

A Japanese patent application filed by モダリス for a compact transcriptional activation module used in CRISPR-GNDM® has received a decision to grant a patent. This strengthens the intellectual property foundation for the technology in Japan.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

CRISPR-GNDM®, novel transcriptional activator, transcriptional activation module
Applicable field (uses covered by this announcement)

Tissue-selective epigenome editing using AAV vectors and transcriptional regulation of genes

Relationship between the counterparty and the company
Modalis Therapeutics Corporation4883
Relationship with the Company

The Company filed the patent application and received a decision to grant a patent from the Japan Patent Office

CounterpartyJapan Patent Office

Japan's patent administration authority, which issued the decision to grant the patent. Other details: not disclosed

Registration number and expiry date

Japanese Patent Application No. 2021-506361; International Publication No. WO 2020/032057. Registration number and validity period: not disclosed

Impact on Business Performance

There is no statement that the impact on business results is minor, and specific details of the impact on business results are not disclosed

The company does not address Contract Value / Offering price.

Announced details
ItemDetails
Names of Products / Services CoveredCRISPR-GNDM®, novel transcriptional activator, transcriptional activation module
CounterpartyJapan Patent Office
Counterparty overviewJapan's patent administration authority, which issued the decision to grant the patent. Other details: not disclosed
Relationship with the CompanyThe Company filed the patent application and received a decision to grant a patent from the Japan Patent Office
Applicable areaTissue-selective epigenome editing using AAV vectors and transcriptional regulation of genes
Registration number and expiry dateJapanese Patent Application No. 2021-506361; International Publication No. WO 2020/032057. Registration number and validity period: not disclosed
Impact on Business PerformanceThere is no statement that the impact on business results is minor, and specific details of the impact on business results are not disclosed
Items this document does not state (11)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleQuantitative EffectsUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The technology miniaturizes the transcriptional activation module so that the necessary components fit within the limited payload capacity of an AAV vector, enabling them to be incorporated into a single AAV vector.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Decision to Grant a Japanese Patent for Technology Related to CRISPR-GNDM | Modalis Therapeutics Corporation (4883) timely disclosure | Komori